Suppr超能文献

KIAA1429调控肝细胞癌中癌症相关基因的可变剪接事件。

KIAA1429 regulates alternative splicing events of cancer-related genes in hepatocellular carcinoma.

作者信息

Liu Zhao-Chen, Li Lu-Hao, Li Ding-Yang, Gao Zhi-Qiang, Chen Dong, Song Bin, Jiang Bing-Hua, Dang Xiao-Wei

机构信息

Department of Hepatobiliary and Pancreatic Surgery, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.

Center for Genome Analysis, Wuhan Ruixing Biotechnology Co. Ltd, Zhengzhou, China.

出版信息

Front Oncol. 2022 Nov 25;12:1060574. doi: 10.3389/fonc.2022.1060574. eCollection 2022.

Abstract

Hepatocellular carcinoma (HCC) remains one of the most fatal malignancies with high morbidity and mortality rates in the world, whose molecular pathogenesis is incompletely understood. As an RNA-binding protein participating in the processing and modification of RNA, KIAA1429 has been proved to be implicated in the pathogenesis of multiple cancers. However, how KIAA1429 functions in alternative splicing is not fully reported. In the current study, multi-omics sequencing data were used to analyze and decipher the molecular functions and the underlying mechanisms of KIAA1429 in HCC samples. RNA sequencing data (RNA-seq) analysis demonstrated that in HCCLM3 cells, alternative splicing (AS) profiles were mediated by KIAA1429. Regulated AS genes (RASGs) by KIAA1429 were enriched in cell cycle and apoptosis-associated pathways. Furthermore, by integrating the RNA immunoprecipitation and sequencing data (RIP-seq) of KIAA1429, we found that KIAA1429-bound transcripts were highly overlapping with RASGs, indicating that KIAA1429 could globally regulate the alternative splicing perhaps by binding to their transcripts in HCCLM3 cells. The overlapping RASGs were also clustered in cell cycle and apoptosis-associated pathways. In particular, we validated the regulated AS events of three genes using clinical specimens from HCC patients, including the exon 6 of BPTF gene and a marker gene of HCC. In summary, our results shed light on the regulatory functions of KIAA1429 in the splicing process of pre-mRNA and provide theoretical basis for the targeted therapy of HCC.

摘要

肝细胞癌(HCC)仍然是世界上发病率和死亡率极高的最致命恶性肿瘤之一,其分子发病机制尚未完全明确。作为一种参与RNA加工和修饰的RNA结合蛋白,KIAA1429已被证明与多种癌症的发病机制有关。然而,KIAA1429在可变剪接中如何发挥作用尚未有充分报道。在本研究中,利用多组学测序数据来分析和解读KIAA1429在肝癌样本中的分子功能及潜在机制。RNA测序数据(RNA-seq)分析表明,在HCCLM3细胞中,可变剪接(AS)图谱由KIAA1429介导。KIAA1429调控的可变剪接基因(RASGs)富集于细胞周期和凋亡相关通路。此外,通过整合KIAA1429的RNA免疫沉淀和测序数据(RIP-seq),我们发现KIAA1429结合的转录本与RASGs高度重叠,这表明KIAA1429可能通过在HCCLM3细胞中结合其转录本来全局调控可变剪接。重叠的RASGs也聚集在细胞周期和凋亡相关通路中。特别地,我们利用肝癌患者的临床标本验证了三个基因的可变剪接调控事件,包括BPTF基因的外显子6和一个肝癌标志物基因。总之,我们的结果揭示了KIAA1429在mRNA前体剪接过程中的调控功能,并为肝癌的靶向治疗提供了理论依据。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/524b/9732450/56acd6dc7b43/fonc-12-1060574-g001.jpg

相似文献

1
KIAA1429 regulates alternative splicing events of cancer-related genes in hepatocellular carcinoma.
Front Oncol. 2022 Nov 25;12:1060574. doi: 10.3389/fonc.2022.1060574. eCollection 2022.
2
KIAA1429 facilitates metastasis via m6A-YTHDC1-dependent RND3 down-regulation in hepatocellular carcinoma cells.
Cancer Lett. 2024 Mar 1;584:216598. doi: 10.1016/j.canlet.2023.216598. Epub 2024 Jan 14.
4
KIAA1429 regulates the migration and invasion of hepatocellular carcinoma by altering m6A modification of ID2 mRNA.
Onco Targets Ther. 2019 May 7;12:3421-3428. doi: 10.2147/OTT.S180954. eCollection 2019.
7
circ_KIAA1429 accelerates hepatocellular carcinoma advancement through the mechanism of mA-YTHDF3-Zeb1.
Life Sci. 2020 Sep 15;257:118082. doi: 10.1016/j.lfs.2020.118082. Epub 2020 Jul 10.
8
KIAA1429 acts as an oncogenic factor in breast cancer by regulating CDK1 in an N6-methyladenosine-independent manner.
Oncogene. 2019 Aug;38(33):6123-6141. doi: 10.1038/s41388-019-0861-z. Epub 2019 Jul 8.
9
Differential alternative splicing regulation among hepatocellular carcinoma with different risk factors.
BMC Med Genomics. 2019 Dec 20;12(Suppl 8):175. doi: 10.1186/s12920-019-0635-z.
10
CELF1 preferentially binds to exon-intron boundary and regulates alternative splicing in HeLa cells.
Biochim Biophys Acta Gene Regul Mech. 2017 Sep;1860(9):911-921. doi: 10.1016/j.bbagrm.2017.07.004. Epub 2017 Jul 19.

引用本文的文献

本文引用的文献

1
METTL3 preferentially enhances non-mA translation of epigenetic factors and promotes tumourigenesis.
Nat Cell Biol. 2022 Aug;24(8):1278-1290. doi: 10.1038/s41556-022-00968-y. Epub 2022 Aug 4.
3
Wnt-TCF7-SOX9 axis promotes cholangiocarcinoma proliferation and pemigatinib resistance in a FGF7-FGFR2 autocrine pathway.
Oncogene. 2022 May;41(20):2885-2896. doi: 10.1038/s41388-022-02313-x. Epub 2022 Apr 15.
4
Immunotherapies for hepatocellular carcinoma.
Cancer Med. 2022 Feb;11(3):571-591. doi: 10.1002/cam4.4468. Epub 2021 Dec 24.
5
Inhibition of YTHDF2 triggers proteotoxic cell death in MYC-driven breast cancer.
Mol Cell. 2021 Aug 5;81(15):3048-3064.e9. doi: 10.1016/j.molcel.2021.06.014. Epub 2021 Jul 2.
6
FGF19 and FGFR4 promotes the progression of gallbladder carcinoma in an autocrine pathway dependent on GPBAR1-cAMP-EGR1 axis.
Oncogene. 2021 Jul;40(30):4941-4953. doi: 10.1038/s41388-021-01850-1. Epub 2021 Jun 23.
8
PTBP3 Induced Inhibition of Differentiation of Gastric Cancer Cells Through Alternative Splicing of Id1.
Front Oncol. 2020 Aug 18;10:1477. doi: 10.3389/fonc.2020.01477. eCollection 2020.
10

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验